Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10311)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PARK7
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Lung cancer | ICD-11: 2C25 | |||
Responsed Drug | 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
In Vitro Model |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
PC-9 cells | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HCC1937 cells | Breast ductal carcinoma | Homo sapiens | CVCL_0290 | ||
BEL-7402 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_5492 | ||
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
RCC4 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0498 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.
Click to Show/Hide
|
||||
Response regulation | The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs. | ||||
Experiment 2 Reporting the Ferroptosis Target of This Regulator | [3] | ||||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
HCCLM3 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | ||
THLE-2 cells | Normal | Homo sapiens | CVCL_3803 | ||
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | ||
SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | ||
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
In Vivo Model |
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.
Click to Show/Hide
|
||||
Response regulation | CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment. | ||||
Prostaglandin G/H synthase 2 (PTGS2) [Driver; Marker]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Marker | ||||
Responsed Disease | Parkinson disease | ICD-11: 8A00 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | ||
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | ||
NCI-H292 cells | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | ||
NCI-H838 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1594 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
KHOS cells | Osteosarcoma | Homo sapiens | CVCL_2546 | ||
A2780 cells | Ovarian endometrioid adenocarcinoma | Homo sapiens | CVCL_0134 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.
Click to Show/Hide
|
||||
Response regulation | KD of DJ-1 (PARK7) increases ferroptosis as PTGS2 levels increased. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease. | ||||
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Parkinson disease protein 7 (PARK7) | Protein coding | |||
Responsed Drug | 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
In Vitro Model |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
PC-9 cells | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HCC1937 cells | Breast ductal carcinoma | Homo sapiens | CVCL_0290 | ||
BEL-7402 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_5492 | ||
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
RCC4 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0498 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.
Click to Show/Hide
|
||||
Response regulation | The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs. | ||||
Parkinson disease [ICD-11: 8A00]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | Parkinson disease protein 7 (PARK7) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | ||
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | ||
NCI-H292 cells | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | ||
NCI-H838 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1594 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
KHOS cells | Osteosarcoma | Homo sapiens | CVCL_2546 | ||
A2780 cells | Ovarian endometrioid adenocarcinoma | Homo sapiens | CVCL_0134 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
Tumors were established by a subcutaneous injection of shRNA (control or DJ-1 KD) transfected H1299 cells (1,000,000/200 uL) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). Twelve days after injection, mice were randomly allocated into different groups and treated with vehicle (0.625% DMSO/99.375% HBSS (pH = 2)) or 30 mg/kg PE (tail intravenous injection, once every other day) for 16 days before the final tumor size was measured in all groups.
Click to Show/Hide
|
||||
Response regulation | KD of DJ-1 (PARK7) increases ferroptosis as PTGS2 levels increased. DJ-1 mutant neuronal cells experience high levels of ferroptosis, which might establish a potential mechanism via which DJ-1 could regulate early-onset recessive Parkinsons disease. | ||||
Hepatocellular carcinoma [ICD-11: 2C12]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [3] | ||||
Target Regulator | Parkinson disease protein 7 (PARK7) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
HCCLM3 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_6832 | ||
THLE-2 cells | Normal | Homo sapiens | CVCL_3803 | ||
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | ||
SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | ||
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
In Vivo Model |
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.
Click to Show/Hide
|
||||
Response regulation | CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment. | ||||
1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione)
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Unspecific Target | ||||
Responsed Disease | Lung cancer | ICD-11: 2C25 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
In Vitro Model |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
PC-9 cells | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | ||
MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
HCC1937 cells | Breast ductal carcinoma | Homo sapiens | CVCL_0290 | ||
BEL-7402 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_5492 | ||
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
RCC4 cells | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0498 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
Tumors were established by injecting 200 uL of H1299 cell suspensions (2 x 106) into BALB/c female athymic nude mice (5 weeks, National Rodent Laboratory Animal Resource, Shanghai, China). When the tumor volume reached an average size of 80 mm3, tumor-bearing mice were subsequently randomly divided into three groups (n = 7 for each group). STK or DM10 was intratumorally administered as a single agent in mouse tumors at a dose of 30 or 15 mg/kg only once.
Click to Show/Hide
|
||||
Response regulation | The PARK7 gene (encode DJ-1 protein) was first discovered as an oncogene and later found to be a causative gene for autosomal recessive early onset Parkinson's disease. 1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione) (DM10) is identified as a potent inhibitor targeting DJ-1 homodimer with the potential as sensitizing agent for other anticancer drugs. | ||||
References